Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Biogen Inc.'s quarterly P/E stands at 21.3x, up 2.2% year-over-year. EV/EBITDA has expanded 117.3% YoY to 14.2x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 22.26 | 21.32 | — | 11.05 | 7.22 | 20.86 | 20.89 | 18.22 | 14.49 | 19.97 | 37.83 | — | 17.50 |
| — | +2.2% | — | -39.4% | -50.2% | +4.5% | -44.8% | — | -17.2% | -23.3% | +107.1% | — | +148.5% | |
| P/S Ratio | 2.96 | 2.74 | 2.83 | 2.10 | 1.73 | 2.05 | 2.28 | 2.87 | 3.43 | 3.43 | 3.95 | 3.68 | 4.22 |
| — | +33.7% | +24.5% | -26.8% | -49.5% | -40.2% | -42.4% | -22.0% | -18.7% | -16.2% | -0.0% | -4.6% | +46.5% | |
| P/B Ratio | 1.58 | 1.46 | 1.41 | 1.13 | 1.04 | 1.18 | 1.34 | 1.73 | 2.13 | 2.07 | 2.55 | 2.57 | 2.87 |
| — | +24.0% | +5.8% | -34.5% | -51.2% | -43.1% | -47.5% | -32.7% | -25.7% | -29.4% | -15.2% | -15.1% | +14.0% | |
| P/FCF | 14.15 | 9.76 | 11.61 | 4.20 | 31.75 | 23.52 | 8.04 | 8.78 | 14.50 | 18.19 | — | 18.43 | 25.90 |
| — | -58.5% | +44.4% | -52.1% | +119.0% | +29.3% | — | -52.4% | -44.0% | -29.9% | — | +14.8% | +142.5% | |
| EV / EBITDA | 11.72 | 14.23 | 24.91 | 7.15 | 7.08 | 6.55 | 9.59 | 10.93 | 18.35 | 11.14 | 16.85 | 23.91 | 14.07 |
| — | +117.3% | +159.6% | -34.6% | -61.4% | -41.2% | -43.1% | -54.3% | +30.5% | -30.6% | +5.3% | +127.7% | +73.6% | |
| EV / EBIT | 17.56 | 18.21 | — | 9.34 | 6.05 | 8.79 | 13.10 | 15.63 | 11.91 | 14.76 | 23.85 | 39.41 | 17.93 |
| — | +107.1% | — | -40.3% | -49.2% | -40.4% | -45.1% | -60.3% | -33.6% | -30.7% | +41.8% | +212.4% | +87.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Biogen Inc.'s operating margin was 16.0% in Q1 2026, up 18.5 pp QoQ and down 14.1 pp YoY. Gross margin contracted 3.8% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.5% | 73.3% | 78.2% | 64.3% | 64.2% | 76.2% | 76.2% | 74.1% | 61.2% | 78.3% | 74.1% | 73.9% | 75.9% |
| — | -3.8% | +2.6% | -13.2% | +4.9% | -2.6% | +2.9% | +0.2% | -19.3% | +7.1% | -4.5% | -9.0% | -6.7% | |
| Operating Margin | 19.1% | 16.0% | -2.5% | 25.0% | 22.2% | 30.1% | 20.7% | 23.4% | 14.9% | 30.1% | 21.5% | 12.7% | 28.1% |
| — | -46.8% | -112.1% | +6.8% | +49.5% | -0.0% | -3.4% | +84.6% | -47.1% | +29.2% | -2.2% | -63.4% | -22.4% | |
| Net Margin | 13.2% | 12.9% | -2.1% | 19.0% | 24.0% | 9.9% | 10.9% | 15.8% | 23.7% | 17.2% | 10.5% | -2.7% | 24.1% |
| — | +30.3% | -119.5% | +20.6% | +1.3% | -42.4% | +3.8% | +685.4% | -1.7% | +9.1% | -51.6% | -105.9% | -41.1% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.4% | 1.7% | -0.3% | 2.6% | 3.7% | 1.4% | 1.6% | 2.4% | 3.8% | 2.6% | 1.7% | -0.5% | 4.2% |
| — | +21.3% | -116.5% | +8.0% | -2.3% | -45.5% | -5.5% | +612.0% | -10.4% | -8.2% | -59.5% | -105.1% | -54.3% | |
| ROA | 4.5% | 1.1% | -0.2% | 1.6% | 2.3% | 0.9% | 0.9% | 1.4% | 2.2% | 1.5% | 0.9% | -0.3% | 2.4% |
| — | +26.4% | -117.4% | +15.0% | +3.0% | -41.8% | +4.3% | +652.2% | -8.0% | -6.7% | -59.3% | -105.6% | -45.3% | |
| ROIC | 6.5% | 1.4% | -0.2% | 2.2% | 2.1% | 2.6% | 1.8% | 2.1% | 1.3% | 2.5% | 1.9% | 1.3% | 2.9% |
| — | -48.3% | -111.0% | +5.2% | +57.6% | +6.6% | -3.7% | +64.4% | -54.2% | -2.9% | -27.7% | -68.7% | -30.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Biogen Inc.'s Debt/EBITDA ratio is 12.3x, down from 23.3x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 112.9% YoY to 3.06x, strengthening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 0.35 | 0.38 | 0.36 | 0.37 | 0.39 | 0.40 | 0.41 | 0.42 | 0.46 | 0.50 | 0.53 | 0.46 |
| — | -9.8% | -4.1% | -11.0% | -10.8% | -14.6% | -20.0% | -23.7% | -8.0% | -4.8% | +0.4% | +2.5% | -28.4% | |
| Debt / EBITDA | 2.47 | 12.29 | 23.26 | 8.08 | 8.43 | 7.23 | 9.57 | 8.75 | 12.68 | 8.29 | 11.25 | 17.31 | 8.16 |
| — | +70.0% | +143.1% | -7.7% | -33.5% | -12.8% | -14.9% | -49.4% | +55.3% | -13.9% | +15.3% | +158.4% | +15.8% | |
| Current Ratio | 2.68 | 3.06 | 2.68 | 2.72 | 2.50 | 1.44 | 1.35 | 1.26 | 2.29 | 2.10 | 2.00 | 1.68 | 3.27 |
| — | +112.9% | +98.7% | +115.7% | +9.4% | -31.3% | -32.5% | -25.2% | -30.1% | -35.3% | -33.2% | -32.3% | +68.6% | |
| Quick Ratio | 2.03 | 2.41 | 2.03 | 2.04 | 1.79 | 1.01 | 0.90 | 0.80 | 1.48 | 1.32 | 1.26 | 1.09 | 2.86 |
| — | +139.0% | +124.9% | +154.3% | +20.8% | -23.2% | -28.4% | -26.2% | -48.1% | -53.2% | -51.1% | -49.0% | +69.6% | |
| Interest Coverage | 8.80 | 6.17 | -0.84 | 9.27 | 12.61 | 11.37 | 8.46 | 8.89 | 13.21 | 9.14 | 6.45 | 4.24 | 12.90 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into BIIB consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BIIB stock.
Biogen Inc.'s current P/E is 22.3x. The average P/E over the last 3 quarters is 13.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Biogen Inc.'s current operating margin is 19.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Biogen Inc.'s business trajectory between earnings reports.